THE EVALUATION OF SERUM ASPROSIN CONCENTRATION IN MINOR ISCHEMIC STROKE

Abstract

Asprosin is a recently identified glucogenic protein adipokine which released into the circulatory system, mainly from the white adipose tissue under fasting conditions and impacts on peripheral and central organs. The purpose of our study was to determine serum asprosin level in minor ischemic stroke. Methods: We recruited 30 patients suffering from minor ischemic attack within the first 24 hours and 28 healthy induvidials as a control group. The blood samples were obtained two times from the patients within the first and the third day, and one time from the control group. The asprosin concentration was determined by a commertially available Enzyme-Linked Immunosorbent Assay (ELISA). Accordingly, obtained datas have been statistically evaluated by SPSS 22.0. Results: The first day’s asprosin levels were significantly higher then the third day’s in the patients group (p<0.013) and the first day’s asprosin levels of the patients group were significantly higher then the control group (p<0). Conclusion: Our results demonstrated that asprosin level is increased at the beginning of minor ischemic stroke when compared to the control group. Additionaly asprosin level is decreased over time as shown in the difference between the first and the third day’s of asprosin in the patients group. The results might lead to broader studies to strenghten the role of asprosin and enhance the knowledge related to the underlying processes of ischemic stroke.